This student paper was written as an assignment in the graduate course

Free Radicals in Biology and Medicine

(77:222, Spring 2005)

offered by the

Free Radical and Radiation Biology Program B-180 Med Labs The University of Iowa Iowa City, IA 52242-1181 Spring 2005 Term

Instructors: GARRY R. BUETTNER, Ph.D. LARRY W. OBERLEY, Ph.D.

with guest lectures from: Drs. Freya Q . Schafer, Douglas R. Spitz, and Frederick E. Domann

The Fine Print:

Because this is a paper written by a beginning student as an assignment, there are no guarantees that everything is absolutely correct and accurate.

In view of the possibility of human error or changes in our knowledge due to continued research, neither the author nor The University of Iowa nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Readers are encouraged to confirm the information contained herein with other sources.

All material contained in this paper is copyright of the author, or the owner of the source that the material was taken from. This work is not intended as a threat to the ownership of said copyrights.

Hypoxia-Inducible Factor



by Suwimol Jetawattana

Department of Radiation Oncology Free Radical and Radiation Biology The University of Iowa Iowa City, IA 52242-1181 For 77:222, Spring 2005 24 March 2005

Hypoxia-Inducible Factor (HIF)

- The major actor in the cellular response to low O₂ (hypoxia) by regulates the expression of many molecules that are involved in glucose transport, glycolysis, erythropoisis, iron transport and angiogenesis
- First discovered during the studies of human erythropoitin enhancer in response to hypoxia

Semenza GL, Wang GL. (1992) Mol Cell Biol. 12(12):5447-5454.

Basic Characteristics

- Transcription factor
- Heterodimeric DNA binding protein
 - Constitutive nuclear subunit (HIF-1β) (also called aryl hydrocarbon receptor nuclear translocator, ARNT) : 91-94 kDa
 - Hypoxia subunit (HIF-1α) : 120 kDa


Wang GL, Semenza GL. (1995) J Biol Chem. 270:1230-1237.

Regulation of HIF-1 α protein synthesis

Growth-factor binding to a cognate receptor tyrosine kinase activates the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways.

PI3K activates the downstream serine/threonine kinases AKT (also known as protein kinase B (PKB) and mammalian target of rapamycin (mTOR).

Semenza GL. (2003) Nature Reviews Cancer (3): 721-732.



■In the MAPK pathway, the extracellular-signal-regulated kinase (ERK) is activated by the upstream MAP/ERK kinase (MEK). ERK, in turn, activates MNK. ERK and mTOR phosphorylate p70 S6 kinase (S6K) — which, in turn, phosphorylates the ribosomal S6 protein — and the eukaryotic translation initiation factor 4E (eIF-4E) binding protein (4E-BP1).


■Binding of 4E-BP1 to eIF-4E inactivates the latter, inhibiting cap-dependent mRNA translation. Phosphorylation of 4E-BP1 prevents its binding to eIF-4E. MNK phosphorylates eIF-4E and stimulates its activity directly. The effect of growth-factor signalling is an increase in the rate at which a subset of mRNAs within the cell (including HIF-1 mRNA) are translated into protein.

Schematic representation of human HIF-1 α , HIF-2 α , and ARNT.

HIF-1α	17 70 106 15 <mark>bHLH</mark> PAS A		401 603 ODD	786 826
	14 67 104 157	250 301	517 682	826 870
HIF- 2α	bhlh PAS A	PAS B	ODD	ID CAD
	91 144 1	71 223 359	410	582 774
ARNT			S B	TAD

HIF-1α, HIF-2α, and ARNT are basic-Helix-Loop-Helix-Per-ARNT-Sim (bHLH-PAS) proteins that contain an N-terminal bHLH domain and two PAS domains that are required for dimerization and DNA binding. HIF-1α and HIF-2α also contain an oxygen-dependent degradation domain (ODD) that mediates oxygen-regulated stability, and a C-terminal transactivation domain (CAD) whose transcriptional repression in normoxia is controlled by the inhibitory domain (ID). ARNT has a transactivation domain (TAD) that serves no function in the context of HIF-α activity. Amino acid numbers for each domain are indicated.

Oxygen-dependent degradation of HIF-1α's



Fedele AO, Whitelaw ML. Peet DJ. (2002) Molecular Interventions. 2:229-243.

Normoxic conditions and the degradation of HIF- $\!\alpha$

- HIF-α is constantly being made
- If O₂ is adequate, HIF-α is marked for degradation by hydroxylation reaction
- HIF-1α is hydroxylated by O₂-, 2-oxoglutarate-, ascorbate-, and Fe²⁺dependent prolyl-4-hydroxylase (PHDs) at proline residues 402 and 564.
- The hydroxylations target HIF-1α for binding with Von Hippel-Lindau protein (VHL) subunit of the Ubiquitine E3 ligase that mediates its rapid proteolysis by the 26S proteasome in cytoplasm.
- Activity of these PHDs is dependent on the presence of regular concentration of oxygen (O₂) and Fe²⁺.

Normoxic conditions and the degradation of HIF- $\!\alpha$

- Binding to VHL are also enhanced by the acetylation of the Lys532 by the ARD1 acetyltransferase, suggesting that the acetylation of HIF-1α by ARD1 is critical to proteasomal degradation.
- Therefore, the role of ARD1 in the acetylation of HIF-1α provides a key regulatory mechanism underlying HIF-1α stability.


Jeong JW, et al. (2002) Cell. 111:709–720.

Iron chelators (ciclopirox olamine, CPX) and CoCl₂ prevent HIF-1α degradation

Baby SM, et al. (2003) Cell Biol. 120:343–352. Yang DI, et al. (2004) Br J Pharmacol. 141:988–996.

Oxygen-dependent transcriptional inactivation of HIF-1α

In the presence of oxygen, β-hydroxylation of the C-terminal Asn803 located in the transactivation domain of HIF-1α by the hydroxylase factor inhibiting HIF-1 (FIH-1) factor, inhibits its transcriptional activity by preventing the binding of the co-activator p300 Mahon PC, et al. (2001) Genes Dev. 15:2675–2686. Lando D, et al. (2002) Genes Dev. 16:1466–1471.




Under hypoxia, the required O₂ tension for asparaginyl hydroxylase activity is deficient. As a result, CBP/p300 can associate with the unhydroxylated CAD and potentiate transcriptional activity.

Fedele AO, Whitelaw ML. Peet DJ. (2002) Molecular Interventions. 2:229-243.

target gene

HRI

If HIF- α is not degraded, it translocates to the nucleus and initiates gene expression




Fedele AO, Whitelaw ML. Peet DJ. (2002) Molecular Interventions. 2:229-243.

Hypoxic conditions stabilization of HIF-1 α

- α subunit is induced only when O₂ below ~ 6%
- When there is not enough O₂ present in the cell to hydroxylate HIF-1α by the PHDs, HIF-1α cannot bind to VHL. It then translocates from the cytoplasm to dimerize with HIF-1β subunit in the nucleus (slide 9).
- With the association of the transcriptional co-activators (CBP/P300), the dimer will bind to the hypoxia responsive element (HRE) of HIF target genes and activate the transcription of these genes (slide 9).

Example of genes that are transcriptionally activated by HIF-1

More than 60 putative direct HIF-1 target genes have been identified.



Adapted from Semenza GL. (2003) Nature Reviews Cancer (3): 721-732.

HIF-1 α can be overexpressed

HIF-1α is overexpressed in many solid tumors, presumably as a result of hypoxia within the tumor

Zhong H. et al. (1999) Cancer Res. 59:5830–5835. Talks KL. et al. (2000) Am. J. Pathol. 157:411–421

- Genetic alteration in tumor can increase HIF-1 activity by decreased ubiquitination or increase synthesis
 - Loss of function: VHL, P53, PTEN, ARF
 - Gain of function: SRC, ERBB2

Semenza GL. (2003) Nature Reviews Cancer (3): 721-732.

It has been suggested that the glycolytic end products lactate and pyruvate may induce HIF-1α accumulation

Lu H. et al. (2002) J Biol Chem. 277:23111–23115.

It has been proposed that the observed increase in glycolytic enzyme expression is caused by constitutive HIF-1α activity

Minchenko A. et al. (2002) J Biol Chem. 277: 6183–6187.

Direct HIF-1 target genes that are particularly relevant to cancer

Metabolic adaptation

ALDA, ENO1, GADPH, GLUT1, GLUT3, GPI, HK1, HK2, LDHA, PFKBF3, PFKL, PGK1, PGM, TPI

Apoptosis resistance

ADM, EPO, ET1, IGF2, NOS2, TGFA

Angiogenesis

EG-VEGF, ENG, LEP, TGF-b3, VEGF, VEGFR2

Invasion/matastasis

AMF, CATHD, CMET, FN1, KRT14, 18, 19, MMP2, UPAR, VIM

Semenza GL. (2003) Nature Reviews Cancer (3): 721-732.

HIF influence diseases

- The expression of HIF-1α is correlated to tumor vascularity
- HIF-1α appears to be involved in fibrinogen-induced VEGF expression in the development of choroidal neovascularization associated with age-related macular degeneration

Shiose S. et al. (2004) Graefes Arch Clin Exp Ophthalmol. 242:777-783.

- Loss of function mutation of the VHL gene leads to HIF-1α accumulation and overexpression of HIF-1α target genes
- Von Hippel-Lindau (VHL) disease affected individuals develop a variety of tumors such as Haemangioblastomas of the central nervous system, Clear cell carcinoma of the kidneys, and Pheochromocytoma of the adrenal glands *Kaelin Jr WG. (2002) Nat Rev Cancer. 2:673-683.*
- Cardiomyocytes and cardiac stromal cells exhibit a marked potential for a prolonged transcriptional response to ischemia mediated by HIF.

Jurgensen JS. et al. (2004) FASEB J. 2004 Sep;18(12):1415-7

Detection of HIF-1 α

Protein level

- western blot analysis
- immunohistochemistry
- immunofluorescence

mRNA level

northern blot analysis

Summary

HIF-1 is a heterodimeric protein that consists of HIF-1 α and HIF-1 β

HIF-1 activates the transcription of more than 60 genes that code for proteins that are involved in angiogenesis, glucose metabolism, cell proliferation/survival and invasion/metastasis

HIF-1 protein synthesis is regulated by activation of the phosphatidylinositol 3-kinase (PI3K) and ERK mitogen-activated protein kinase (MAPK) pathways or by signalling via receptor tyrosine kinases, non-receptor tyrosine kinases or G-protein-coupled receptors.

HIF-1 protein degradation is regulated by O₂-dependent prolyl hydroxylation, which targets the protein for ubiquitylation by E3 ubiquitin-protein ligases.

HIF-1 is overexpressed in human cancers as a result of intratumoral hypoxia as well as genetic alterations.